Asia-Pacific lung cancer screening software market is projected to register a CAGR of 20.6% in the forecast period of 2020 to 2027. The new market report contains data for historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
Asia-Pacific Lung Cancer Screening Software Market, By Mode of Delivery (Cloud Based Solutions, On-Premise Solutions and Web Based Solutions), Product (Lung Cancer Screening Radiology Solution, Lung Cancer Screening Patient Management Software, Nodule Management Software, Data Collection and Reporting, Patient Coordination and Workflow, Lung Nodule Computer Aided Detection, Pathology and Cancer Staging, Statistical Audit Reporting, Screening PACS, Practice Management and Audit Log Tracking), Type (Computer-Assisted Screening and Traditional Screening), Application (Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)), Platform (Standalone and Integrated), Purchase Mode (Institutional and Individual), End User (Oncology Centers, Hospitals, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender and Third Party Distributor), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific) Industry Trends and Forecast to 2027
Some of the major factors contributing to the growth of the Asia-Pacific lung cancer screening software market are:
- Government initiatives undertaken to implement screening programs for various diseases
- Technological advancements in the field of healthcare
Market Players
The key market players for Asia-Pacific lung cancer screening software market are listed below:
- Medtronic
- PenRad Technologies Inc.
- Koninklijke Philips N.V.
- Volpara Solutions Limited
- Lungview
- Siemens Healthcare Private Limited
- Thynk Health, Eon
- Nuance Communications, Inc.
- MeVis Medical Solutions AG
- Vital Images (A Subsidiary of Canon Group company)
- HealthMyne
- Optellum Ltd
- MyCareWare
- ProVation Medical, Inc.
